Kudryavtsev M.YU.

Kudryavtsev M.YU.

Auto-generated profile, based on publicly available information

Kudryavtsev M.YU.

N.P. Ogarev National Research Mordovia State University, Saransk, Russian Federation

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
SESamishina E.A.
Samishina E.A.
DODeryabina O.N.
Deryabina O.N.
KMKudriavtzev M.Y.
Kudriavtzev M.Y.
TOTumutolova O.N.
Tumutolova O.N.
EBEkaterina Blinova
Ekaterina Blinova
The work identified potential molecular targets for the implementation of the antitumor effect of a new domestic compound, an analogue of pyridine LHT-13-19. Using the "Autodock 4.2" software environment, flexible receptor-directed molecular biological docking was carried out in virtual reality, which makes it possible to most accurately predict the formation of a complex between a molecular structure and a biological target in real conditions of a specific biological system. For molecular docking, three-dimensional structures of the epidermal growth factor receptor (EGFR, PDB ID: 1M17, 4KN2) from the open electronic library Protein Data Bank (USA) were used. The ligands were prepared using the MGL Tools 1.5.6 software environment, and their optimization was performed using the Avogadro software (USA). The molecule of the compound, an analogue of pyridine nucleoside, was synthesized in the Department of Chemistry, Technology of Synthetic Medicines and Analytical Control of All-Union Research Center for Biological Active Compounds Safety (Russia). As a result of the experiments, it was found that the LHT-13-19 molecule forms a conformational intermolecular interaction with the active centers 1M17, 4KN2 of the epidemic growth factor EGFR. The affinity is based on the formation of hydrogen and electron-acceptor bonds, characterized by high values of the scoring function and free energy value. Moreover, in terms of the strength of the affinity, the LHT-13-19 substance is not inferior to the reference molecule erlotinib.

19 September 2022 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
KMKudryavtsev M.YU.
Kudryavtsev M.YU.
TOTumutolova O.N.
Tumutolova O.N.
DODeryabina O.N.
Deryabina O.N.
EAEpishkina A.A.
Epishkina A.A.
VOVavilova O.S.
Vavilova O.S.
EBEkaterina Blinova
Ekaterina Blinova
. In the study, the pharmacological activity of the pyridine derivative LHT-17-19 was studied in relation to the culture of pancreatic cancer cells PANC-1 and the culture of bladder cancer cells HT-29 expressing the epidermal growth factor receptor. The cultures were obtained from the library of tumor strains of the Moscow Research Institute of Oncology. P.A. Herzen - a separate structural subdivision of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia. LHT-17-19 was synthesized in the Department of Chemistry, Technology of Synthetic Medicines and Analytical Control of JSC VNTs BAV (Russia). LHT-17-19 and the reference drug "Doxorubicin" 50 mg each were added to the cultivation medium in the concentration range from 10-8 to 10-v. Compounds LHT-17-19 were shown to be able to induce death and suppress the growth of pancreatic cancer squamous culture (PANC-1) and bladder (HT-29) tumor cells expressing EGFR over a wide range of concentrations. So for pancreatic cancer (PANC-1), the effective inhibitory concentration for the compound LHT-17-19 was 1.3 × 10-7 M, while for the reference substance doxorubicin it was 6.0 × 10-5 M. bubble (NT-29) - 2.4 × 10-7 M and 5.2 × 10-4 M, respectively.

19 September 2022 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
DODeryabina O.N.
Deryabina O.N.
KMKudryavtsev M.YU.
Kudryavtsev M.YU.
TOTumutolova O.N.
Tumutolova O.N.
EBEkaterina Blinova
Ekaterina Blinova
EAEpishkina A.A.
Epishkina A.A.
DBDmitry Blinov
Dmitry Blinov
In the work, a pre-experimental screening of pyridinecarboxylic acid derivatives was performed by the PASS program, The work identified potential molecular targets for the implementation of the antitumor effect of a new domestic compound, an analogue of pyridine LHT-13-19. Using the "Autodock 4.2" software environment, flexible receptor-directed molecular biological docking was carried out in virtual reality, which makes it possible to most accurately predict the formation of a complex between a molecular structure and a biological target in real conditions of a specific biological system. For molecular docking, three-dimensional structures of the epidermal growth factor receptor (EGFR, PDB ID: 1M17, 4KN2) from the open electronic library Protein Data Bank (USA) were used. Molecules of compounds - pyridine derivatives LHT-13-19, LHT-16-19 and LHT-17-19 were synthesized in the Department of Chemistry, All-Union Research Center for Biological Active Compounds Safety (Russia). As a result of the experiments, it was found that all the studied molecules have inhibitory activity against proto-oncogenic kinases, however, in terms of the totality of predictive characteristics, as well as the likelihood of forming an antitumor effect, LHT-17-19, which was studied in docking studies, turned out to be the most promising compound. It was shown that LHT-17-19 has a high affinity for the epidermal growth factor kinase receptor EGFR-K, exhibits an affinity for the CSF1 receptor system, superior to that of all comparators - imatinib, erlotinib and pemetrexed. Also, in the process of docking approach and subsequent docking with the active site of tyrosine kinase EGFR-K and the human folate receptor FOLR2, an additional hydrogen bond is formed inside the LHT-17-19 molecule between the hydrogen proton of the amino group and the oxygen atom of the carbonyl group with atomic distances of 2.21 Å and 2 .49 Å, respectively.

30 December 2021 in Bulletin "Biomedicine and sociology"
Verified
Journal Article
Closed access
KMKudriavtzev M.Y.
Kudriavtzev M.Y.
DODeryabina O.N.
Deryabina O.N.
SESamishina E.A.
Samishina E.A.
AKArutiunian K.K.
Arutiunian K.K.
EAEpishkina A.A.
Epishkina A.A.
The work studied the antitumor activity of a new compound, a pyridine derivative LHT-13-19. To determine the effective inhibitory concentration, a culture of human colon cancer HCT116 was used. Incubation of tumor cells was carried out in the presence of LHT-13-19 in the concentration range from 10-9 to 10-7 M. The survival of tumor cells was determined in MTT test. In vivo experiments were performed on thirty athymic humanized 12-week-old female BALB/c nu/nu mice with xenograft colorectal adenocarcinoma. All animals were divided into 3 groups, 10 mice in each: animals of the control group were injected daily intraperitoneally with 0.5 ml of PBS, animals of the second group were treated with a cyclophosphamide at a dose of 10 mg/kg, mice of the third the groups received LHT-13-19 as experimental therapy at a daily dose of 3.7 mg/kg during 10 days. Animals’ survival and antitumor activity were assessed. Tumor-doubling time, the number of liver superficial metastases and survival time were estimated. Daily incubation of human colon tumor cells with LHT-13-19 is accompanied by the formation of the cytotoxic effect of the compound. On a xenograft model of colon adenocarcinoma in humanized BALB/c nu/nu mice, a 10-day course of 3.7 mg/kg LHT-13-19 leads to the formation of an antitumor effect due to increase in the time of tumor doubling, animal survival and a decrease in the frequency of metastasis